Drugs / Bacillus Calmette-Guerin
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05714202 Comparator | Mar 2023 → Sep 2029 expected | urinary bladder cancer | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bacillus Calmette-Guerin | “Treatment Group B: Bacillus Calmette-Guerin (BCG) Vesiculture” NCT05714202 ↗ |
| Known as | BCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05714202 ↗ |
| Route | Other | “BCG will be administered intravesically.” NCT05714202 ↗ |